Equities Analysts Issue Forecasts for GPCR FY2025 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Structure Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($1.09) per share for the year. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share.

Several other equities analysts also recently issued reports on the company. Citigroup started coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Finally, HC Wainwright lowered their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $76.50.

Structure Therapeutics Trading Up 6.4%

Structure Therapeutics stock traded up $1.32 during midday trading on Tuesday, reaching $21.83. 1,048,215 shares of the stock traded hands, compared to its average volume of 863,662. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $54.08. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -29.50 and a beta of -1.87. The firm has a fifty day moving average price of $22.07 and a two-hundred day moving average price of $24.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

Institutional Trading of Structure Therapeutics

Several institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its position in Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after acquiring an additional 203,010 shares in the last quarter. Deep Track Capital LP boosted its holdings in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after buying an additional 1,579,492 shares in the last quarter. Vestal Point Capital LP grew its position in Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after buying an additional 63,990 shares during the last quarter. Capital International Investors increased its holdings in shares of Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company's stock valued at $43,909,000 after buying an additional 103,059 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after buying an additional 322,601 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.